Two of the leading developers of drugs for the treatment of autism are partnering to combine efforts in the development and marketing of drugs aimed at relieving some behavioral problems associated with autism and fragile X syndrome. At least one line of drugs based on mGluR5 antagonists expected to come out of the partnership between Roche and Seaside Therapeutics will likely end up competing with drugs under development by Novartis, which is said to be further along in developing a treatment that blocks the mGluR5 receptors in the brain thereby dampening the signals received (presumably making life a bit easier for the patients using it.) Read more about it at nytimes.com here:
http://www.nytimes.com/2012/06/19/health/roche-and-seaside-team-up-to-develop-autism-drugs.html
No comments:
Post a Comment